← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Theralogics, Inc.
Chapel Hill, NC
$3,665,717
Total funding
6
Grants
Funding over time
peak $944.8K · FY2006–13$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$3,665,717 · 6
By mechanism
R42$2,528,177 · 2
R41$1,137,540 · 4
Investigators at Theralogics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease$698,128
R42 · FY2012 · DK
Validation of a Novel NF-kB Inhibitor in Inflammatory Bowel Disease$698,128
R42 · FY2013 · DK
Inhibition of IkK to treat lethal Graft-vs.-Host Disease$454,379
R42 · FY2009 · AI
Inhibition of IkK to treat lethal Graft-vs.-Host Disease$442,778
R42 · FY2008 · AI
Evaluation of NBD Peptides as an Adjunct Therapy for the Treatment of Non-Hodgkin$420,475
R41 · FY2010 · AI
NF-kB Inhibition of Lung Ischemia Repurfusion Injury$255,627
R41 · FY2009 · HL
Blockade of NF-kappaB for Prevention/Treatment of GVHD$244,488
R41 · FY2006 · AI
Inhibition of IkK to treat lethal Graft-vs.-Host Disease$234,764
R42 · FY2009 · AI
Validation of a Novel NF-KB Inhibitor in Murine IBD$216,950
R41 · FY2006 · DK